If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.00    0.00 (0.00%)
Bid:
11.50
Ask:
12.50
Spread: 1.00 (8.696%)
Market Cap: £15.02m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

30 Apr 2007 07:03

Fabian Romania Property Fund Ltd30 April 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €60 million office building inBucharest Fabian Romania has reached agreement to purchase its fourth office project, theCubic office development (the "Cubic Centre"), in Bucharest. The Cubic Centrewill be a class A office building with a gross area of approximately 44,000square metres, located in North Bucharest. The building is being developed bythe Kendama, an experienced local developer in Romania. Construction hascommenced and completion is anticipated in the second quarter of 2009. The Cubic Centre will upon completion of construction provide a net lettableoffice area of 27,000 square metres over 12 floors, together with 533 carspaces. The building is located in a prominent location in the Pipera districtof North Bucharest and is likely to attract international tenants seeking classA office space. Vacancy rates for class A office space in in Bucharest are lessthan 3%. The acquisition is due to complete, subject to certain conditions, in twostages. The Fund will pay a first instalment of €12.25 million, of which €5million has already been paid in the form of a secured loan. At practicalcompletion of the building by the developer, the Fund will pay the finalinstalment based upon a forward purchase yield of 7.4% - 7.8% applied to rentsachieved. Based upon current rental estimates, the total value of thetransaction is estimated to be approximately of €60 million. The total equityrequirement for the fund is estimated to be €12 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed its first investment since Admissionto AIM on favourable terms in what is a highly competitive market. The CubicCentre will provide a high quality addition to the Fund's portfolio of officebuildings. It will also give diversification geographically within the city bothin terms of building type and expected tenant mix." Mark Owen, Director responsible for acquisitions comments: "The new office development is in a prominent location in the rapidly expandingoffice location of the northern Pipera district of the City. This area will befurther enhanced by the new motorway link into the City. The Cubic Centre,which is already under construction on a fixed price basis, is well positionedto capitalise on the demand for Class A office space expected. We are already inearly discussions with a number of quality tenants seeking to upgrade theiroffice accommodation." The lead advisers on the transaction were Eurisko (property agent), WSP(technical advisers) and NNDKP (legal adviser). END For Comments:Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLP +44 20 7936 3000James Lewis Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Jan 20214:41 pmRNSSecond Price Monitoring Extn
12th Jan 20214:35 pmRNSPrice Monitoring Extension
20th Nov 20207:00 amRNSHalf-year Report
17th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSNotice of Results
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:36 pmRNSPrice Monitoring Extension
27th Oct 20207:00 amRNSReceipt of grants from Invest Northern Ireland
25th Sep 202011:38 amRNSResult of AGM
24th Sep 20202:39 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:16 pmRNSHolding(s) in Company
18th Sep 20209:31 amRNSUpdate on R&D programme
28th Aug 20207:00 amRNSNotice of AGM
19th Aug 20207:00 amRNSFinal Results
11th Aug 20209:33 amRNSQueens University Belfast funding
31st Jul 20205:00 pmRNSTotal Voting Rights
7th Jul 20202:12 pmRNSExercise of Options
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSTrading update
4th Jun 202012:57 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
21st May 20206:24 pmRNSHolding(s) in Company
21st May 20202:52 pmRNSHolding(s) in Company
15th May 20204:49 pmRNSHolding(s) in Company
15th May 202010:47 amRNSResult of General Meeting & Total Voting Rights
15th May 20208:30 amRNSHolding(s) in Company
28th Apr 20207:00 amRNSPlacing to raise £3m, trading update, notice of GM
17th Apr 20204:41 pmRNSSecond Price Monitoring Extn
17th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20203:51 pmRNSResearch Alliance with Queen’s University Belfast
16th Apr 20202:06 pmRNSSecond Price Monitoring Extn
16th Apr 20202:01 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSTrading update
19th Mar 20207:00 amRNSBelfast investor presentation
17th Mar 20207:00 amRNSDirector/PDMR Shareholding
17th Feb 20207:00 amRNSBelfast investor presentation
3rd Feb 202012:01 pmRNSDirector/PDMR Shareholding
30th Jan 20204:40 pmRNSSecond Price Monitoring Extn
30th Jan 20204:35 pmRNSPrice Monitoring Extension
29th Jan 20207:00 amRNSTrading update
10th Jan 202011:47 amRNSDirector/PDMR Shareholding
3rd Dec 20199:26 amRNSDirector/PDMR Shareholding
2nd Dec 20197:00 amRNSHalf-year Report
26th Nov 201911:13 amRNSNotice of Results
22nd Oct 20197:00 amRNSHalf year trading update
26th Sep 20199:54 amRNSDirector/PDMR Shareholding
20th Sep 20192:14 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.